Leung, Sherman S., Borg, Danielle J., McCarthy, Domenica A., Boursalian, Tamar E., Cracraft, Justen, Zhuang, Aowen, Fotheringham, Amelia K., Flemming, Nicole, Watkins, Thomas, Miles, John J., Groop, Per-Henrik, Scheijen, Jean L., Schalkwijk, Casper G., Steptoe, Raymond J., Radford, Kristen J., Knip, Mikael, and Forbes, Josephine M. (2022) Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells. Diabetes, 71 (9). pp. 1994-2008.

Preview

PDF (Published Version) - Published Version Download (1MB) | Preview

 

7

507

Abstract

Type 1 diabetes is an autoimmune disease with no cure, where clinical translation of promising therapeutics has been hampered by the reproducibility crisis. Here, short-term administration of an antagonist to the receptor for advanced glycation end products (sRAGE) protected against murine diabetes at two independent research centers. Treatment with sRAGE increased regulatory T cells (Tregs) within the islets, pancreatic lymph nodes, and spleen, increasing islet insulin expression and function. Diabetes protection was abrogated by Treg depletion and shown to be dependent on antagonizing RAGE with use of knockout mice. Human Tregs treated with a RAGE ligand downregulated genes for suppression, migration, and Treg homeostasis (FOXP3, IL7R, TIGIT, JAK1, STAT3, STAT5b, CCR4). Loss of suppressive function was reversed by sRAGE, where Tregs increased proliferation and suppressed conventional T-cell division, confirming that sRAGE expands functional human Tregs. These results highlight sRAGE as an attractive treatment to prevent diabetes, showing efficacy and reproducibility at multiple research centers and in human T cells.

Actions (Repository Staff Only)

Item Control Page